ICCM$0.7898-6.29%
IceCure Medical Ltd.
Sector: Surgical & Medical Instruments & ApparatusIndustry: Medical - DevicesCountry: ILExchange: Nasdaq
Mkt Cap:$3.66M
Float & O/S:
Inst Own:
DilutionScan read 62 of IceCure Medical Ltd.'s SEC filings and found 9 warrant series, 3 ATM programs, 2 shelf registrations, 2 S-1 registrations and 2 completed offerings on file for ICCM. The latest dilution event on file is a registration statement on Jul 2, 2026. Analysis updated Oct 5, 2026.
Signal8 Summary
ICCM
Reverse split and critical cash runway
Snapshot
IceCure is a micro-cap medical device company burning cash much faster than it earns it. FY 2025 revenue was $3.4M but the company posted a $15.1M net loss, largely due to R&D spending that is more than double its total sales.
What's Happening Right Now
- : IceCure raised $5.5M in a private placement priced at $3.00 per share with a single institutional investor, issuing warrants alongside the shares.
- : The company reported a 70% increase in its US active commercial install base for the ProSense system following FDA clearance and updated clinical guidelines.
- : IceCure announced a 1-for-30 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, reducing outstanding shares from about 84.2 million to 2.8 million.
- : Data presented at ECIO 2026 showed an 89.4% recurrence-free rate for kidney cancer patients treated with ProSense, supporting broader commercial adoption.
- : Nasdaq granted IceCure a 180-day extension to regain compliance with the minimum bid price requirement, pushing the deadline to November 9, 2026.
